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A B S T R A C T 
 
A DAND5-control human iPSC line was generated from the urinary cells of a phenotypically normal donor. 
Exfoliated renal epithelial (RE) cells were collected and reprogrammed into iPSCs using Sendai virus repro- 
gramming system. The pluripotency, in vitro differentiation potential, karyotype stability, and the transgene-free 
status of generated iPSC line were analyzed and confirmed. This cell line can be exploited as a control iPSC line to 
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This DAND5-control iPSC line is essential in studying the disease 
related impairment in heart formation of DAND5 found in a previous study. 
This control cell line will allow to uncover the role of DAND5 
c.455 G > A variant in the molecular mechanisms of cardiomyocyte 




DAND5 is a Nodal antagonist that is involved in the correct left/ right 
body axis establishment during gastrulation (Belo et al., 2017). The heart 
is the first organ to be formed and the first organ to be af- fected by 
improper levels of Nodal signaling throughout embryo de- velopment. 
Several variants of different genes involved in this signaling pathway 
have been associated with Congenital Heart Disease (Deng   et al., 2015). 
Recently, we have identified and functionally character- ized a c.455G 
> A DAND5-variant in a patient diagnosed with ven- tricular septal 
defect with overriding aorta, right ventricular hyper- trophy, and 
pulmonary atresia (a case of extreme tetralogy of Fallot phenotype) 
(Cristo et al., 2017a). The variant was inherited from the apparently 
healthy mother. To further study the impact of altered DAND5 proteins 
in molecular pathways that are involved in cardiac development and on 
cardiomyocyte behavior, we have generated and characterized the 
NMSUNLi001-A variant cell line, which has a het- erozygous non-
synonymous variant in exon 2 of DAND5 gene  (c.455G > A), causing 
an amino acid change of p.R152H in the func- tional domain of the 
DAND5 protein (Cristo et al., 2017b). However, to unveil the precise 
mechanism of how this variant affects early heart development, the 
generation of control iPSC lines is essential. Here, we generated and 
characterized a DAND5 patient-related (father) control iPSC line that 
does not carry any alteration in the locus of the variant described in the 
NMSUNLi001-A cell line. This cell line will be utilized for disease 
modeling purpose. Hence, exfoliated renal epithelial (RE) cells were 
collected from urine sample collected from a healthy donor. After being 
grown during 7 days in culture, the RE cells were repro- grammed using 
CytoTune™-iPS 2.0 Reprogramming Kit (Life Technol- ogies, 
Invitrogen). The kit utilizes non-transmissible, non-integrating form of 
Sendai Virus (SeV) vectors that deliver four key transcription factors 
(SOX2, OCT3/4, c-MYC and KFL-4) to reprogram the somatic cells into 
a pluripotent state, and the iPSC colonies appeared 17 days after the 
delivery of the reprogramming factors. At this time, we ob- served that 
cells assumed typical stem cell morphology. To obtain homogeneous and 
clonal iPSCs lines, we manually picked and expanded several single cell-
derived iPSCs colonies. Among those, one sub-clone that best displayed 
the ESC-like morphology (Fig. 1A) was chosen for further 
characterization. Firstly, after 27 passages in culture, DNA Sanger 
sequencing and karyotype analysis proved the genotype 455G in DAND5 
exon 2 (Fig. 1D), and the number (46, XY) and arrangement of 
chromosomes (Fig. 1C). We assessed the transgene-free status of the 
iPSC line by qPCR (Fig. 1E), confirming the clearance of the viral 
vectors. Since the cytoplasmic nature of SeV only allows the exogenous 
reprogramming vectors to be cleared after several passages, we used an 
early passage of iPSCs as a positive control. The pluripotency of the cells 
was analyzed by both fluorescence immunocytochemistry (Fig. 1F) and 
qPCR (Fig. 1B). We confirmed the expression of the key plur- ipotency 
factors OCT4, NANOG, and SSEA4 both at protein and mRNA level.  At  
mRNA  level,  we  additionally  contfihremexpression  of pluripotency 
markers NODAL and SOX2. Embryoid body (EB) forma- tion assay was 
performed to assess the spontaneous differentiation potential of the 
iPSCs in vitro. From this assay, we assessed that the EBs cultured for 19 
days expressed markers of the three germ layers: en- doderm, mesoderm, 
ectoderm, i.e., alpha-fetoprotein (AFP), smooth muscle actin (SMA), 
tubulin beta-3 chain (TUBB3),  respectively  (Fig. 1G). Finally, STR 
analysis was performed showing that all the 16 loci tested matched 
(Table 1).  
 
  Materials and methods 
 
Reprogramming of RE cells 
 
RE cells were collected and expanded in culture. After ~4 days in 
culture, cells started to become evident and the medium was changed to 
REBM™ supplemented with REGM™ BulletKit (Lonza). When cells 
reached ~80% confluency, they were seeded on a 6-well plate and 
reprogrammed using CytoTune™-iPS 2.0 Sendai Reprogramming Kit 
(Life Technologies). At day 8 post-transduction, cells were passaged 
onto a 100 mm culture dish coated with Geltrex (Gibco, Thermo Fisher 
Scientific) and the next day medium was changed to Essential 8™ (E8) 
Flex medium, replaced until the iPSCs have emerged. 17 days post- 
transduction, colonies that best display an ESC-like morphology were 




To confirm the absence of the c.455G nucleotide in the established 
DAND5-control cell line, genomic DNA was extracted using ISOLATE II 
Genomic DNA kit (Bioline). Then, using the primers indicated in Table 
2, exon 2 of DAND5 was amplified by PCR and purified using 
NZYGelpure kit (NZYTech). Sequencing was conducted by STAB VIDA 
(http://www.stabvida.com/). 
 
RNA extraction and real time qRT-PCR 
 
The clearance of SeV transgenes and the expression of pluripotency 
markers OCT4, NANOG, SSEA4 (primers listed in Table 2) were carried 
out using Direct-zol™ RNA MiniPrep (Zymo Research). Subsequently, 
reverse transcription and qRT-PCR were performed. 
 
Embryoid body formation assay 
 
Embryoid bodies (EBs) consisting of approximately 2000 iPS cells/ 
20 μl drop in Essential 8™ (E8) medium with 4 mg/ml polyvinylalcohol 
and RevitaCell™ Supplement (Thermo Fisher Scientific) were generated 
using hanging drop method. After 2 days, EBs were suspended in 50% 
E8 medium and 50% differentiation medium (DMEM with 20% FBS, 
Pen/Strep, NEAA, 2 mM L-glutamine, and 0,1 mM β-mercaptoethanol) 
and grown 3 more days. At day 5, EBs were placed on 24-well-plate 
with differentiation medium changes every other day. By day 19, EBs 
were fixed with 4% formaldehyde and the immunocytochemistry as- 
sayed for the three germ layers AFP, SMA and TUBB3. 
 
Fluorescent immunocytochemistry (ICC) 
 
Cells were fixed with 4% paraformaldehyde, permeabilized, blocked 
and incubated with primary and secondary  antibodies  (listed  in  Table 
2) overnight at 4 °C. Prior to image acquisition, DAPI was used to stain 




Chromosome analysis was performed using GTG high resolution 
banding technique, according to standard procedures with a minimum of 
10 metaphase spreads analyzed. Analysis of GTG-banded chromo- 
somes was performed at a resolution of 400 bands per haploid genome 
and karyotypes were established according to the International System 
for Human Cytogenetic Nomenclature (ISCN 2016). 
 





Fig. 1. Characterization of the iUC-DAND5_455/control iPSC line. A. Morphology of the iUC-DAND5_455/control line. B. mRNA expression levels of endogenous 
pluripotency markers in H9 cells (Black - positive control), ERE cells (Blue) and iUC-DAND5_455/control line (Red). CT-values were normalized to the geometric mean 
of the two housekeeping genes GAPDH and β-actin and with H9 human embryonic stem cell line as reference (set to 1). C. Karyotype of representative metaphase 
showing normal 46 chromosomes (XY). D. DNA sequence confirming the normal homozygous c.455G genotype in the iUC-DAND5_455/control line. E. Absolute 
quantitative real-time PCR showing absence of the vectors and the exogenous reprogramming factor in iPSCs (right) and presence of the reprogramming factors in the 
EREr control cells (left). F. Immunodetection of pluripotency markers of iUC-DAND5_455/control line. G. Immunofluorescence analyses of in vitro differentiation of 
EBs using specific antibodies against the endodermal marker α-fetoprotein (AFP), ectodermal marker βIII-tubulin  (TUBB3)  and mesodermal markers α-smooth muscle 
actin (SMA). Nuclei were stained with DAPI (scale bars = 20µm). 





Characterization and validation. 
Classification Test Result Data 
 
Morphology Photography ESC-like morphology Fig. 1, panel A 
Phenotype Immunocytochemistry Staining of pluripotency markers: Oct4, Nanog, SSEA4 Fig. 1, panel F 
qPCR Expression of pluripotency markers: NANOG, OCT3/4, SOX2, KLF4 and 
NODAL 
Fig. 1, panel B 
Genotype Karyotype (G-banding) and resolution 46XY, Resolution 400–500 Fig. 1, panel C 
Identity Microsatellite PCR (mPCR) N/A 
STR analysis 16 loci analyzed, all matching Supplementary Fig. S1 panel 
A 
Mutation analysis (IF 
APPLICABLE) 
Sequencing Homozygous (G > G) Fig. 1, panel D 
Southern  Blot OR WGS N/A, Non-integrating reprogramming methodology 
Microbiology and virology Mycoplasma contamination Mycoplasma-free culture Supplementary Fig. S1 panel 
B 
Differentiation potential Embryoid body formation Proof of formation of three germ layers from Embryoid bodies: α- 
fetoprotein (AFP), βIII-tubulin (TUBB3), α-smooth muscle actin (SMA). 
Fig. 1, panel G 
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A 
Genotype additional info 
(OPTIONAL) 
Blood group genotyping N/A N/A 











Company Cat # and RRID 
 
Pluripotency Markers Rabbit anti-NANO 1:200 Abcam Cat# ab21624, RRID:AB_446437 
 
 Rabbit anti-OCT4 1:400 Abcam Cat# ab19857, RRID:AB_445175  
 Mouse anti-SSEA4 1:200 Abcam Cat# ab16287, RRID:AB_778073  
Differentiation 
Markers 
Mouse anti-Human TUBB3 1:400 Sigma-Aldrich Cat# T8660, RRID:AB_477590  
 Mouse anti-Human SMA 1:600 Dako Cat# M0851, RRID:AB_2223500  
 Rabbit anti-Human AFP 1:200 Dako Cat# A0008, RRID:AB_2650473  
Secondary antibodies Alexa Fluor 488-conjugated Donkey anti-Mouse IgG (H + 
L) 




Jackson ImmunoResearch Labs Cat# 715–545-150, 
RRID:AB_2340846 




    
Target Forward/Reverse primer (5′-3′) 
Elimination  of  Sendai  Virus transgenes (qPCR) Sev GGATCACTAGGTGATATCGAGC/ACCAGACAAGAGTTT AAGAGATATGTATC 
Sev-KLF4 TTCCTGCATGCCAGAGGAGCCC/AATGTATCGAAGGTG CTCAA 
Sev-C-MYC TAACTGACTAGCAGGCTTGTCG/TCCACATACAGTCCT GGATGATGATG 
Sev-KOS ATGCACCGCTACGACGTGAGCGC/ACCTTGACAATC CTGATGTGG 





House-Keeping Genes (qPCR) GAPDH CTGGTAAAGTGGATATTGTTGCCAT/TGGAATCATATTGGAACATGTAAACC 
β-actin GCAAAGACCTGTACGCCAAC/AGTACTTGCGCTCAGGAGGA 
Mycoplasma  detection Pair 1 CTGCAGATTGCAAAGCAAGA/CCTCCTTCTTCACCTGCTTG 
Pair 2 GGCGAATGGGTGAGTAACACG/CGGATAACGCTTGCGACCTATG 




Mycoplasma contamination test 
 
The sterility of the iPSC culture from mycoplasma was verified by 




iUC-DAND5_455/control cells and the corresponding ERE cells were 
authenticated by STR analysis performed by STAB VIDA (http://www. 
stabvida.com/). 
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Congenital heart diseases (CHDs) and associated laterality defects are a major health 
concern and 1,35 million people are diagnosed with CHDs each year worldwide. The 
complexity of heart development and the hurdles to investigate the disease phenotypes 
make it challenging to identify the underlying causes of CHDs. 	
DAND5 is the human homologue of mouse Cerl-2 gene that codes for a protein involved 
in regulating the Nodal signalling pathway by antagonizing the Nodal protein in the node 
and inhibiting the Nodal signaling in the right lateral plate mesoderm (R-LPM). In a 
previous study, a new DAND5 heterozygous nonsynonymous variant c.455G>A was 
identified and linked to the risk of disease in two patients with CHDs arising from 
laterality defects. In order to model the phenotype of the patients with the 
variant c.455G>A, a human iPSC line was previously generated and characterized 
(Cristo et al., 2017).	
In this work,	we characterized a DAND5-control iPSC line from a healthy male donor 
(without the variant) to serve as control for the DAND5 c.455G>A line.	
The characterization was based on the detection of pluripotency markers at gene- and 
protein level, and in vitro differential potential. Short tandem repeats (STR) analysis has 
used to prove the genetic identity of the ERE cells and the reprogrammed iPSCs. 
Karyotyping of the iPSCs after ≥20 passages has shown the stability of the highly 
proliferating iPSCs. Additionally, Mycoplasma detection test showed the sterility of the 
cell culture.	
 	
This control cell line will be compared to the DAND5 variant c.455G>A cell line to 
further exploit our knowledge on the consequences of the variant in the phenotypes of the 
patients (disease modelling) and more precisely in the modulation of cardiomyocyte 










As doenças cardíacas congênitas (DCC) e os defeitos de lateralidade associados são uma 
das principais preocupações de saúde e 1,35 milhões de pessoas são diagnosticadas com 
DCC a cada ano em todo o mundo. A complexidade do desenvolvimento do coração e os 
obstáculos para investigar os fenótipos da doença tornam difícil identificar as causas 
subjacentes das DCC. 
O gene DAND5 é o homólogo humano do Cerl-2 de camundongo que codifica uma 
proteína envolvida na regulação da via de sinalização Nodal antagonizando a proteína 
Nodal no nódulo e inibindo a sinalização Nodal na mesoderme da placa lateral direita (R-
LPM). Em um estudo anterior, uma nova variante não-sinônima c.455G> A da DAND5 
heterozigótica foi identificada e vinculada ao risco de doença em dois pacientes com DCC 
decorrentes de defeitos de lateralidade. Para modelar o fenótipo dos pacientes com a 
variante c.455G> A, uma linha iPSC humana foi previamente gerada e caracterizada 
(Cristo et al., 2017). 
Neste trabalho, caracterizamos uma linha iPSC de controle DAND5 de um doador do sexo 
masculino sadio (sem a variante) para servir de controle para a linha DAND5 c.455G> 
A. 
A caracterização foi baseada na detecção de marcadores de pluripotência a nível de genes 
e proteínas, e potencial diferencial in vitro. A análise de repetições curtas em tandem 
(STR) usou para provar a identidade genética das células ERE e das iPSCs 
reprogramadas. A cariotipagem das iPSCs após ≥ 20 passagens mostrou a estabilidade 
das iPSCs altamente proliferativas. Além disso, o teste de detecção de Mycoplasma 
mostrou a esterilidade da cultura de células. 
 
Esta linha celular de controlo será comparada com a linhagem celular c.455G> A da 
variante DAND5, para explorar ainda mais o nosso conhecimento sobre as consequências 
da variante nos fenótipos dos doentes (modelação da doença) e, mais precisamente, na 









ActRII: activin A receptor type 2 
AFP: alpha fetoprotein 
ALK4: activin A receptor type 1B 
AoS: aortic stenosis 
A/P: anterior/posterior 
AP: arterial pole 
APC: adenomatous polyposis coli 
ARC105: mediator complex subunit 15 
AS: aortic sac 
ASD: atrial septal defect 
AV: atrioventricular 
AVE: anterior visceral endoderm 
AVR: atrioventricular ring 
AVSD: atrioventricular septal defects 
A-P: anterior-posterior 
BL-2: Biosafety Level 2 
BSA: bovine serum albumin 
Ccnd1: cyclin D1 
cDNA: complementary deoxyribonucleic acid 
Cerl-2: cerberus-like 2 
CFC1: cripto, FRL-1, cryptic family 1 
CHDs: Congenital Heart Diseases 
CITED2: Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal 
domain 2 
c-Myc: MYC proto-oncogene, bHLH transcription factor 
CM: cardiomyocyte 
CNS: central nervous system 
CK1: casein kinase 1 
Coarc: coarctation 
Cripto: teratocarcinoma-derived growth factor 1 
DAPI: 4′,6-diamidino-2-phenylindole 
DAND5: Dan domain family member 5 
DL: dextral looping 
DMEM: Dulbecco's Modified Eagle Medium 
DMSO: dimethyl sulfoxide 
DNA: deoxyribonucleic acid 
dNTP: deoxyribonucleotide triphosphate 
DORV: double outlet right ventricle 
Drp1: dynamin 1 like 
DV: dorsoventral 
DVL: dishevelled 
EBs: embryoid bodies 
EGF-FGF: epidermal growth factor-fibroblast growth factor 
ERE: exfoliated renal epithelial 
ESCs: embryonic stem cells 
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FBS: fetal bovine serum 
FZL: Frizzled 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase  
GATA4: GATA binding protein 4 
GSK3ß: glycogen synthase kinase 3 beta 
hESC: human embryonic stem cell 
hiPSC: human induced pluripotent stem cell 
ICC: immunocytochemistry 
ICM: inner cell mass 
iPSC: induced pluripotent stem cell 
kDa: kilodalton 
Klf-4: kruppel-like factor 4 
KO: knock-out 
KOS: Klf4–Oct3/4–Sox2 
LDEV: lactose dehydrogenase elevating virus  
Lefty1: left-right determination factor 1 
Lefty2: left-right determination factor 2 
LPM: lateral plate mesoderm 
LR: left/right 
LRP5/6: LDL receptor related protein 5 
Nanog: Nanog homeobox 
NEAA: non-essential amino acids 
NF: nuclease-free 
NKX2-4: NK2 homeobox 4 
NKX2-5: NK2 homeobox 5 
Nodal: nodal growth differentiation factor 
NOTCH1: notch 1 
NOTCH2: notch 2 
Oct4: POU class 5 homeobox 1 
PA: primitive atrium 
PAHs: polycyclic aromatic hydrocarbons 
PBS: phosphate-buffered saline 
PCR: polymerase chain reaction 
PDA: patent ductus arteriosus 
PenStrep: penisilin/streptomycin 
Pitx2: paired-like homeodomain 2 
PLV: primitive left ventricle 
Ppm1a: protein phosphatase, Mg2+/Mn2+ dependent 1A 
PR: primary ring 
PRV: primitive right ventricle 
PS: pulmonary stenosis 
PVA: polyvinyl alcohol 
qPCR: quantitative polymerase chain reaction 
RNA: ribonucleic acid 
R-LPM: right lateral plate mesoderm 
ROCK: rho-associated protein kinase 
Rpm: revolutions per minute 
RT: reverse transcriptase 
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RT-qPCR: real time quantitative polymerase chain reaction 
SAR: sinoatrial ring 
SeV: Sendai virus 
SMA: smooth muscle actin 
Smad2: SMAD family member 2 
Smad3: SMAD family member 3 
Smad4: SMAD family member 4 
Sox2: sex determining region Y-box 2 
SSEA4: stage-specific embryonic antigen-4 
SSCs: somatic stem cells 
STR: short tandem repeats 
SV: sinus venosus 
TBX1: T-box 1 
TBX20: T-box 20 
TCL/LEF: T cell factor/lymphoid enhancer factor 
TGA: transposition of the great arteries 
TGF-ß: transforming growth factor beta	
TOF: Tetralogy of Fallot 
TUBB3: class III ß-tubulin 
VAR: ventriculoarterial ring 
VP: venous pole 
VSD: Ventricular Septal Defect 
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1.1. Congenital Heart Diseases 
 
Congenital heart diseases (CHDs) represent the abnormalities of the heart or the great 
vessels at birth, which accounts for 9 of 1,000 live births globally (Linde, Van Der et al., 
2011). This translates into an annual number of 1.35 million live births with CHDs out of 
150 million births in the world. The symptoms of CHDs include shortness of breath, 
fatigue, heart murmur (Sun et al., 2015). CHDs represent a wide range of heart defects 
that include ventricular septal defect, atrial septal defect, pulmonary stenosis, patent 
ductus arteriosus, tetralogy of Fallot, coarctation of aorta, and atrioventricular septal 
defect (Kumar V, Abbas AK, 2012). The most common subtype of CHDs is ventricular 
septal defect (VSD) on a global scale (Abdulkadir & Abdulkadir, 2016; Chelo et al., 
2016), followed by atrial septal defect (ASD) (Linde, Van Der et al., 2011) (Fig. 1.1). 
Laterality defects, another type of CHD, display a prevalence of 1.1 in 10.000 live births 
(Lin et al., 2014) and are caused by the improper left-right axis determination of the 
internal organs during the developmental stage. The disruption of the normal left-right 
axis establishment culminates in a variety of complex cardiac and extracardiac 
aberrations (Versacci et al., 2018). Among these malformations, situs inversus totalis 
occurs when the internal organs develop as their complete mirror images, whereas in situs 
ambiguous (or heterotaxy) the internal thoracic or abdominal organs are assembled 
aberrantly (Vetrini et al., 2016). However, whereas in situs inversus the prevalence of 
CHD is 3%, almost all the patients (90%) with heterotaxy also have complex congenital 
heart defects like pulmonary atresia/stenosis, transposition of the great arteries (TGA), 
double outlet right ventricle (DORV), ventricular septal defects (VSDs), atrial septal 
defects (ASDs), atrioventricular septal defects (AVSD), hypoplastic left heart, anomalous 
venous return and coarctation of the aorta (Mohapatra et al., 2009). 
The aetiology of CHDs is not well understood and characterized in most of the cases, 
nevertheless environmental, genetic and epigenetic factors together are known to play a 
role in the development of the disease. Environmental factors that of maternal origin 
include pregestational diabetes, pollakiuria, febrile illnesses, viral infections such as 
rubella and/or rubeola, influenza, alcohol consumption, cigarette smoking, use of 
medications, and teratogens (Chaix, 2016; Sun et al., 2015). Moreover, recently, maternal 
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hypertension (Ramakrishnan et al., 2015) and maternal exposure to polycyclic aromatic 
hydrocarbons (PAHs) were also been associated with the increased risk of CHDs (Li et 
al., 2018). Among the genetic factors, chromosomal aberrations, single gene mutations 
or deletions are to be listed. Moreover, the patients can be categorized as syndromic and 
non-syndromic phenotypes. In Down, Edward, Patau, DiGeorge syndromes, 
chromosomal aneuploidies are responsible for the CHDs, whereas single gene deletions 
or mutations are the causative of Holt-Oram, Nooan, Allagille syndromes (Chaix, 2016). 
In the, case of non-syndromic patients, mutations in several genes, inherited according to 
Mendelian inheritance, have been shown as the cause of CHDs. Some of them include 
NKX2-4, NKX2-5, CITED2, CFC1, GATA4, TBX1, TBX20, NOTCH1, NOTCH2 whose 
mutations are linked to CHDs (Deng et al., 2014; Djordjevic et al., 2015).  
Additionally, since the major cause of mortality in laterality defects is related to complex 
CHDs, we can postulate that these defects can result from the disturbances of the left-
right axis patterning. Therefore, variants in the genes involved in the establishment of the 
LR axis might also function as a risk factor or as a direct cause of CHDs (Ramsdell, 
2005). 
 
Due to the advances in early diagnostic methods and the availability of pediatric cardiac 
surgery, the mortality rate of the children born with CHDs decreased significantly over 
the last years. Between 1987-2005, the mortality of children with complex CHDs was 
reduced 67%, resulting in an increase of the median age of patients death by 15 years.   
For the first time, the number of adults living with congenital heart diseases is higher than 
children. There are now an estimated 1.8 million adults in Europe with CHDs, and this 
number is expected to increase rapidly in the next years (Ávila et al., 2014; Moons et al., 
2010). This brings several consequences, and adults with congenital heart disease, 
particularly those with moderate or complex disease, presented longer-term sequelae and 
face significant cardiac and noncardiac comorbidities and a shorted life expectancy that 
need be managed with special attention, care and differently than the pediatric patients. 
Moreover, these patients are an important adulthood problem with a high healthcare 





Figure 1.1. Prevelance of Congenital Heart Diseases (CHDs). The results include global data 
of birth prevelance over the period shown in the graph. AoS=aortic stenosis, ASD: atrial septal 
defect, Coarc: coarctation, PDA: patent ductus arteriosus, PS: pulmonary stenosis, TGA: 
transposition of the great arteries, TOF: tetralogy of Fallot, VSD: ventricular septal defect. 
(Obtained from Lin et al., 2014). 
 
In order to discover therapeutic solutions for the CHDs and other cardiac diseases, an 
elaborate knowledge of the heart development is necessary. Moreover, since the heart 
have a limited regeneration capacity and heart transplantation is not always possible due 
to the inadequate organ supplies and immune rejection risk, the need for better 
understanding the cardiac disease mechanisms and the generation of desired amounts of 
cardiomyocytes is urgent.  
Therefore, discovery of patient-specific iPSC raised the hopes that these cells could be 
used in multiple areas of research, disease modelling, drug screening, and translational 
therapies to serve as a solution to those patients. In the future, with the improvements of 
iPSC technology, functional cardiomyocyte generation may be scaled up and the the 
solution for cardiac diseases may be widely available. 
 
1.2. An Overview of Heart Development 
 
A functional heart requires the adequate pumping of the blood to all body parts, which is 
achieved by the coherence of the great vessels and heart chambers. The development of 
the human heart includes numerous steps that begins with the formation of mesoderm at 
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day 12 of gestation and is completed by the 8th week (Kumar V, Abbas AK, 2012). 
Initially, cardiac precursor cells that are located symmetrically in the splanchnic layer of 
the lateral plate mesoderm fuse in the midline and give rise to a primitive heart tube at 
day 17-19 of development in human and day 7 in the mouse embryo (Sylva, Hoff, Van 
den & Moorman, 2014). Afterwards, the heart tube elongates, bends and undergoes 
several looping steps, in order to provide the correct positioning of the atria and the 
ventricles. At the later stages with the addition of ectoderm-derived neural crest cells, 
specification and septation of the heart chambers is achieved, so that, the oxygenated and 
deoxygenated blood will precisely be present in separate chambers, allowing the proper 
functioning of the heart (Sieber-Blum, 2004). 
All of these steps are strictly regulated  and involving many genetic pathways  that are 
highly conserved along the species (Sun & Kontaridis, 2018). Therefore, any impairment 
of these molecular pathways might disrupt the correct formation of the heart, resulting in 
congenital heart diseases (CHDs), the major cause of both infant morbidity and mortality 
in the first year of life (Fixler et al., 2014; Gilboa et al., 2016).  
 
1.2.1. Embryonic Origins of the Heart  
The journey of a human embryo begins with the fertilization of an egg cell with a 
spermatozoid to form a newly specialized cell called the zygote. The zygote undergoes 
repetitive cell divisions without gaining any size, being called morula. As the cell 
divisions of the sphere-shaped morula continue, the cells in the middle unequally take up 
nutrients due to the geometric nature of a sphere and therefore will need a wider surface 
area. At this embryonic stage, called blastocyst, a cavity in the middle part of the diving 
cells is formed, presenting an internal mass of cells called inner cell mass (ICM) or 
embryoblast and an outer cell layer called trophoblast (Fig. 1.2A) (Moore, Persaud & 
Torchia, 2016). Upon the implantation of the embryo into the uterine wall, trophoblast 
cells will undergo proliferation and differentiation and their lineages will mainly give rise 
to the extraembryonic tissues such as placenta (Silva & Serakides, 2016). The cells that 
make up the ICM will then differentiate into hypoblast (or primitive endoderm) and 
epiblast, forming a structure called bilaminar embryonic disc (Fig. 1.2B). The hypoblast 
will contribute to the extraembryonic tissues, whereas the epiblast contains pluripotent 
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cells that will form the three germ layers (i.e. endoderm, mesoderm, and ectoderm) and 
the germ cell lineage (Roode et al., 2012). 
 
At this stage, the epiblast and hypoblast cells of the bilaminar embryonic disc appear as 
a flat disc (Fig. 1.2B). Later on, at the midline of the embryonic disc, a structure called 
primitive streak will form, marking the first morphological sign of the gastrulation 
process. 
 
The primitive streak also determines the anterior-posterior (A/P) axis of the embryo, a 
process that begins by the implantation of the blastocyst into the uterus. Upon 
implantation, in mice, the epiblast cells and the extraembryonic lineages (trophectoderm 
and primitive endoderm) undergo a series of proliferation and form an egg 
cylinder (Beddington e Robertson, 1999; Morris et al., 2012). Once the egg cylinder is 
formed, the epiblast is positioned at the distal part of the embryo, whereas the 
extraembryonic ectoderm, derived from trophectoderm, is located at the proximal part. 
Around E5.5, primitive endoderm-derived anterior visceral endoderm (AVE) cells at the 
distal part of the embryo move unilaterally towards the anterior of the embryo and defines 
the point where the head will form (Srinivas, 2004). At the same time, the dorsoventral 
(DV) axis is specified according to the proximal-distal axis of the implantation 
site (Ferguson, 1996; Meinhardt, 2015). So, after implantation, the future A/P axis is 
marked anteriorly by the polarization of the head primordium and posteriorly (tail) by the 
appearance of the primitive streak, while the prospective DV axis is defined by the 
formation of the three germ layers, the endoderm marking its ventral side and the 
ectoderm being dorsal (Hamada & Tam, 2014; Hirokawa, Tanaka & Okada, 2009) 
Once the A/P and DV axes are established, it is argued that the left-right (LR) axis is 
established consistently oriented relative to the dorsoventral and anterior.  
The patterning of LR axis starts at gastrulation in a process involving the Nodal signalling 
pathway and a leftward flow of secreted molecules in the node that culminates in the 
creation of a LR-biased signal in this embryonic structure. Afterwards, this signal is 
transferred to the lateral plate mesoderm (LPM), and subsequently to internal organs for 
their asymmetric morphogenesis (Raya & Izpisúa Belmonte, 2006). The regulation of this 





Figure 1.2. The developmental stages of the human heart formation. (Adapted from Moore, 
Persaud, Torchia, The Developing Human: Clinically Oriented Embryology, 2016). 
 
 
1.2.2. Lateral Plate Mesoderm (LPM) Formation 
At day 16 of development in humans and E6.5 in mouse, around the midline of the 
epiblast, the primitive streak forms in the posterior region of the embryo (Fig. 1.2B). This 
structure will continue from the midline of the bilaminar embryo to the caudal part. The 
cells around the primitive streak continuously divide laterally and cranially until they 
make up a lining above the hypoblast, forming two bilateral heart-forming regions (Fig. 
1.2C). When the cells in the primitive streak stop dividing, we are left with three different 
layers that are solely derived from the epiblast; ectoderm, mesoderm, and endoderm 
(Schleich et al., 2013). These three germ layers will give rise to the particular parts of the 
developing embryo. Ectoderm mainly will form the epidermis as well as the central 
nervous system (CNS), endoderm will line the gut and respiratory tract and mesoderm 
will give rise to the connective tissue and cardiovascular system. 
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The mesoderm can be divided into somatic mesoderm, intermediate mesoderm, and the 
lateral plate mesoderm (LPM). The somatic mesoderm cells will give rise to somites (Fig. 
1.2C), which will form axial structures like skeleton and skeleton muscles and the 
intermediate mesoderm will form the kidneys and the gonads (Moorman, 2003; 
Musumeci et al., 2015). The lateral plate mesoderm will differentiate into two distinct 
parts, the somatic LPM and the visceral LPM, which will originate the heart and some 
parts of the circulatory system like blood cells and blood vessels (Moorman, 2003).  
 
1.2.3. Two Crucial Steps of the Heart Formation: Fusion of the 
Endocardial Tubes and Heart Looping 
 
As the development of human foetus proceeds, in the visceral LPM, dorsal to the 
developing gut tube, the left and right dorsal aortae will appear, whereas the ventral 
endocardial tubes (or cardiogenic plate, Fig. 1.3A) will be formed ventral to the gut tube. 
The ventral endocardial tubes were initially thought to be symmetrical, but now we know 
that they are not completely symmetrical (Gittenberger-De Groot et al., 2005). They are 
composed of crescent-shaped group of cells, where the first and second heart fields can 
be distinguished. The transition from mesodermal to cardiac progenitor cells requires the 
induction and specification of the splanchnic mesoderm into cardiac mesoderm, which is 
mediated by intrinsic signals from the primitive streak and from the surrounding tissues. 
Upon the fusion of the left and the right endocardial tubes, an arterial pole (AP) at the 
anterior and venous pole (VP) at the posterior will come into existence (Fig. 1.3A). 
During this time, the left and right parts of the ectoderm at the most outer layer of the 





A.   B.    
Figure 1.3. From the endocardial tubes to the chamber specification. A. Endocardial tubes 
emerge at the left and the right side of the embryo. At about day 23 of development they fuse and 
create one single endocardial tube. Venous pole (VP) at the posterior take up the blood and carry 
it to the arterial pole. The rightward (dextral) looping (DL) of the endocardial tube locates the 
heart chambers in their final positions, along with the subsequent septations. B. The spatial 
locations of sinus venosus (SV), primitive atrium (PA), primitive left- and right ventricles (PLV, 
PRV), and aortic sac (AS). Atrioventricular- and ventriculoarterial rings (AVR, VAR) will form 
the valves with the migration of endocardial cushions. (PR: primary ring, SAR: sinoatrial ring). 
(Adapted from Gittenberger-de Groot et al., 2005). 
 
Around day 21 of development, the two endocardial tubes at the left and right side of the 
embryo will start to bind to each other and will fuse completely around day 23. Likewise, 
the two dorsal aortae will also fuse to be in contact with the endocardial tubes via the 1st 
and the 2nd aortic arches.  
At this stage, the heart is still a long tube divided in the sinus venosus (SV), primitive 
atrium (PA), primitive ventricle (PV), bulbus cordis, and the aortic sac (AS) (Fig. 1.3B). 
SV will give rise to the right atrium, vena cavae, and the coronary sinus. PA and PV will 
give rise to the atria and the ventricles of the heart. Bulbus cordis will mostly form the 
right ventricle, whereas the aortic sac constructs the aortic arches. 
The four-chambered heart will form after the looping of the heart. Before the looping, the 
aortic sac is at the superior part of the elongated tube and the sinus venosus in the inferior 
part. During the heart looping, the primordial atrium will end up being superior to the 
primordial ventricle, and at the same time, the bulbus cordis loops to the right side of the 




Rightward cardiac looping is the first morphological indication of asymmetry in the 
vertebrate embryo and the mechanisms that drive this process are intrinsically related 
with the correct establishment of the LR axis during gastrulation. In turn, this correct left 
or right identity depends on a complex network of signals and molecules that are strictly 
regulated and maintained on the LPM in the form of Pitx2 expression, which will be 
described in Section 1.2 (Patel, Isaac & Cooke, 1999). 
The incorrect looping of the endocardial tube at this stage is associated with some of the 
CHDs categorized as laterality defects such as sinus inversus totalis, heterotaxia (Schleich 
et al., 2013).  
 
1.2.4. Maturation of the Heart  
Until this point, the positioning of the heart chambers is partially established. However, 
the septation and the rearrangement of the arteries need to occur for the heart to become 
a fully functional organ that pumps the sufficient blood to nourish all the body. Therefore, 
to achieve this maturation, firstly, the atrioventricular (AV) canal needs to be closed by 
dorsal and ventral endocardial cushions, followed by left and right lateral cushions and 
form the left and right AV canal (Fig 1.3B) (Sieber-Blum, 2004).  
As mentioned before, primordial ventricle and the bulbus cordis will give rise to the left 
and the right ventricles. The looped parts of the endocardial tube, sinus venosus and 
primordial atria will form the right and the left atria. In addition to that, part of bulbus 
cordis will become the proximal aorta and the pulmonary trunk. 
Once the four-chambered heart structure is established, the differentiating myocardium 
will be responsible for the conduction system instead of the peristaltic construction of the 
heart tube (Ya et al., 1997).  
The normal blood circulation will start with the entry of the venous blood from the body 
parts to the right atrium. Via the tricuspid valve, the venous blood will flow to the right 
ventricle and subsequently will be pumped to the lunges by pulmonary arteries. 
Simultaneously, the left atrium takes up the oxygenated blood from the pulmonary veins 
and pumps it to the left ventricle through the mitral valve. The oxygenated blood from 
left ventricle is then pumped to different body parts by aorta.  
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The conduction of the electrical impulses throughout the heart is achieved by nodes. 
Sinoatrial node, atrioventricular node, bundle of His and Purkinje fibers together 
orchestrate the conduction in the heart (Sánchez-Quintana & Yen Ho, 2003).  
At later stages, coronary vascular formation of the heart will be accomplished by 
epicardium. The endothelial network that is derived from the epicardium will provide 
nutrition and oxygen for the heart itself (Tomanek, 2005). 
 
Each and every step of the heart development should be correctly established, since their 

























1.3. Cardiac Left-Right Asymmetry 
Vertebrates have an external bilateral symmetry along the left-right axis but present a left-
right asymmetry of the internal organs (Levin, 2005). Although the first sign of left-right 
asymmetry occurs during the morphogenesis of the internal organs at the time of cardiac 
looping, the specification of the left-right axis takes place much earlier at gastrulation. At 
this time, cells that migrate from the primitive streak to the left and right parts of the 
embryonic midline are already exposed to different left and right patterning signals and 
will contribute to the distinct regions of the heart. These patterning signals, in turn, result 
from a number of events that are mainly controlled by the TGF-ß/Nodal signalling 
pathway and DAND5, a 20-kDa secreted growth factor with the ability to directly bind 
to Nodal and to inhibit its signalling pathways, play a critical role in this process (Hamada 
et al., 2002; Zhou et al., 1993). 
 
1.3.1. Regulation of the Left-Right Axis Formation 
The establishment of the left-right axis can be divided into three main steps; initial 
symmetry breaking at the node, the transfer of the LR-biased signal from the node to the 
LPM, and the left-right asymmetric positioning and morphogenesis of the visceral organs 
(Shiratori & Hamada, 2014).  
 
The initial left-right symmetry breaking seems to originate in a structure called left-right 
organizer (node in amniotes; Kupffer’s vesicle in Zebrafish). According to the widely 
accepted fluid flow model in symmetry breaking, the cells that are aligned along the LR 
organizer create a leftward flow by the motile cilia. This flow, namely nodal flow has 
been shown to be dependent on the motile cilia which reside in the mouse node (Nonaka 
et al., 1998). 
In Figure 1.4, the symmetry breaking mechanism in the vertebrate embryo is depicted. 
In the centre of the LR organizer, motile cilia are responsible to create the leftward nodal 
flow by rotating in a clockwise direction, whereas at the periphery, the immotile sensory 
cilia sense this flow in a mechanosensory way (Zinski, Tajer & Mullins, 2017). As a result 
of this leftward flow, the cells on the left part of the LR organizer degrade RNA of the 
Cerl2 (DAND5), which results in the biased Cerl2 expression on the right side of the LR 
organizer, resulting in the suppression of the Nodal signalling in the right side of the 
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embryo. The second step in the establishment of the LR axis involves the transference of 
the this LR biased signal to the left-LPM. The mechanism of the transduction of this 
signal is currently not known, but it is suggested that the peripheral cells of the LR 
organizer secrete Nodal ligands and the upon receptor binding, Nodal signalling will start 
in the left part of the LPM, where Nodal regulates its own expression by a positive-
feedback mechanism. On the right side of the LPM, this signalling is disrupted by Nodal 
inhibitors, Lefty1 and Lefty2. Lefty1 functions as a midline barrier that prevents Nodal to 
cross the midline and to induce bilateral expression of left-specific genes, whereas Lefty2 
regulates the expression of Nodal in left LPM, restricting the intensity and area of Nodal 
signalling in a highly precise manner (Smith et al., 2011). 
After the LR biased signalling in the node has been accomplished and subsequently 
propagated through the left LPM, the signal must reach to the internal organs and be 
interpreted in order to initiate the asymmetrical morphogenesis of visceral organs.  
The key gene responsible for this 3rd step of the LR axis formation is called Pitx2. As it 
can be seen in Fig. 1.4., Pitx2 is initially expressed in the left LPM, and its expression is 
expanded throughout the whole left LPM. 
The signalling of the asymmetry from the left LPM through to internal organs are 
achieved by Pitx2 expression, which retains longer than other components of Nodal 
signalling pathway. During the next steps of cardiac development, when the primitive 
heart tube undergoes dextral looping to form the four-chambered heart, Pitx2 expression 
is essential. Among the different isoforms of Pitx2, the cardiac-specific Pitx2 (Pitx2c) is 
responsible for this cardiac looping, whose ectopic expression causes laterality defects of 
the heart such as situs inversus and cardiac isomerism (Liu et al., 2001). Moreover, in the 
formation of atrioventricular canal by endocardial cushions, left-sided expression 
of Pitx2 in the myocardium is detected. Additionally, Pitx2c expression was also shown 
in left atrium, left outflow tract, and interventricular myocardium (Ai et al., 2006). 
The abnormal expression of the Pitx2 during the outflow tract rotation, as well as the 
leftward shifting of the heart tube might contribute to a number of congenital heart defects 
(CHDs) such as double outlet right ventricle (DORV), transposition of the great arteries 
(TGA), and ventricular septal defects (VSD). These findings suggest the multifunctional 






Figure 1.4. Nodal signalling pathway components in left-right symmetry breaking in 
vertebrates. (Adapted from Zinski, Tajer & Mullins, 2017).  
 
1.3.2. Nodal Signalling and the Role of DAND5 
The molecular cascade of the Nodal signalling pathway and its components are depicted 
in Fig. 1.5. 
Nodal signalling is activated when the Nodal protein binds to a target cell through 
interaction to the ALK4 (serin-threonine kinase type I receptor) and ActRII (serin-
threonine kinase type I receptor). Upon the receptor-ligand interaction and co-receptor 
involvement (Cripto or Cryptic), ALK4 phosphorylation at the cell membrane occurs. 
This leads to the subsequent phosphorylation of Smad2/Smad3, their association with 
Smad4 and the translocation of this complex to the nucleus. Here, the complex interacts 
with the transcription factor FoxH1 leading to activation of downstream target genes like 
Nodal itself (auto regulation), Lefty2 and Pitx2, which is the main responsible for 
transducing the Nodal signaling afterwards (Hill, 2018; Shen, 2007). 
The Nodal signalling pathway needs to be strictly regulated and this is achieved by the 




Figure 1.5. The components of Nodal signalling pathway. (Obtained from Hill, 2018) 
 
 
Cerberus like 2 (Cerl-2) or DAND5 gene in humans encodes a protein that belongs to the 
TGF-ß (transforming growth factor-ß) antagonists.  
 
As a Nodal antagonist, the secreted Cerl-2 protein plays a crucial role in the determination 
of left-right asymmetry in mice (Marques et al., 2004). At the mouse node, the 
asymmetric expression pattern of Cerl-2 represents the most immediate molecular 
response to the flow. 
 
 
Prior to the appearance of the LR-biased signalling, the levels of Cerl-2 in peripheral 
crown cells are equal on the left and right side of the node. At this stage, the Nodal flow 
achieved by the motile cilia is very weak. As the leftward Nodal flow accelerates (E7.75), 
Cerl-2 expression on the left side is downregulated, which breaks the symmetry of the 
Nodal signalling and creates a LR-bias in the node (E8.0).  
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The resulting Nodal signalling is therefore increased on the left side of the node (L>R), 
due to the relatively higher Nodal-inhibitory effect of Cerl-2 on the right side. 
At the 2/3 somite stage in mice, once the expression of Cerl-2 in the right side of the node 
starts to become higher than the left side, Cerl-2 protein accumulates in the right side of 
the node, preventing the activation of Nodal cascade on the R-LPM (Saijoh et al., 2003). 
When the velocity of the nodal flow becomes intense, it drives the translocation of the 
inhibitory Cerl-2 protein from the right to the left side of the node. This assumption is in 
agreement with the small size (20kDa) of this protein, which may render it easily 
transported (Inácio et al., 2013). Until the 6-somite stage, the Cerl-2 protein remains in 
the left side of the node. By then, the signal starts to decrease and terminate.  
As a summary, Cerl-2 is initially present in the right side of the mouse embryo, where it 
starts its Nodal inhibiting activity. Afterwards, the translocation of the Cerl-2 protein to 
the left LPM turns the Nodal signalling off (Oki et al., 2009).  
 
 
Cerl-2 is initially present in the right side of the mouse embryo, where it starts its Nodal 
inhibiting activity. Afterwards, the translocation of the protein to the left side of the 
embryo turns the Nodal signalling off (Inácio et al., 2013).  
 
The crucial role of Cerl-2 in the establishment of LR axis and consequent heart 
development is supported in the significant mortality rate due to the cardiac defects 
(including laterality defects) seen in Cerl-2 knock-out (KO) mice. Moreover, the absence 
of Cerl-2, the only member of the Cerberus/DAN family expressed in the heart, observed 
in Cerl-2 knock-out mice also results in a massive increase of the ventricular cardiac 
walls, without any laterality defect, suggesting that Cerl2 has a role in heart development 
other than establishing the left-right axis in mice (Arauȷó, Marques & Belo, 2014). 
  
In fact, the hypertrophy of the ventricular walls in Cerl-2 KO mice were shown to be 
caused by increased levels of phospo-Smad2 that culminates in prolonged TGF-ß/Nodal 
signalling. Moreover, the ventricles of these mice also presented an increased mitotic 
index associated with an increased expression of Ccnd1, which functions as a cell cycle 
regulator. Considering that this signalling pathways regulates cardiac proliferation (in 
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addition to its roles in early cardiac specification, and differentiation), the presence of 
Cerl-2 seems to be specifically required in the heart to control the proliferation of 
cardiomyocytes through the control of TGF-B/Nodal signalling. 
In addition to these findings, nuclear ß-catenin levels in the Cerl-2 KO mice was also 
shown to be increased. Wnt/ß-catenin signalling is also an important pathway that 
regulates proliferation and differentiation. Therefore, its upregulation highly affects the 
cardiomyocyte proliferation. 
Overall, the lack of Cerl-2 in mice is associated with the dysregulation of both TGF-




Recently, the human homologue of Cerl-2, DAND5 (Dan domain family member 5) was 
also studied and associated to the risk of developing CHDs in a cohort of CHD patients 
arising from defects during the establishment of the LR axis. In this study, conducted in 
our lab, a heterozygous nonsynonymous nucleotide variant c.455G>A, leading to a 
p.R152H a.a change in the functional domain of the DAND5 protein, has been found in 
two Caucasian patients with CHDs (Cristo et al., 2017). Phenotypically, Proband 1 
presents left isomerism, VSD with overriding aorta, and pulmonary atresia, whereas 
tetralogy of Fallot and pulmonary atresia was observed in Proband 2one of the patients 
(Table 1.1). To get further insight in the consequences of the variant, a functional 
luciferase assay was performing and the results showed  that the c.455G>A variant leads 
to  a decreased activity of the DAND5 protein and consequently an increase in Nodal 
signalling   (Cristo et al., 2017). This means that during the embryonic development of 
the patients, NODAL and DAND5 protein binding might have been less efficient than 
normal, resulting in a reduced inhibitory effect of DAND5 in the node. Equally, NODAL 
could be expressed higher than its normal levels on the node and then in the LPM. It 
remains unknown if the excess level of NODAL was located on the left or right side of 
the LPM, however, from the patients’ phenotypes, it can be concluded that an ectopic 
expression of NODAL (and PITX2) on the right-LPM might have occurred during the 
embryonic stage of the patients. 
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Altogether, these results link for the first time the reduced activity of a DAND5 variant 
with the human vulnerability for CHDs. 
 
 

























1.4. iPSC Technology 
Due to the limitations of accessibility of some tissues in the body, such as the heart and 
the brain, there are diseases that cannot be easily studied. The use of stem cells represents 
a good solution to overcome this problem. 
An important milestone in 1998 was achieved by the isolation and the cultivation of 
embryonic stem cells (ESCs) for the first time (Thomson, 1998). ESCs are pluripotent 
stem cells obtained at a very early stage of development that are capable of differentiating 
into all the cell types in an adult organism, and to proliferate indefinitely. Since ESCs are 
derived from oocytes and embryos their use in research and therapeutic approaches brings 
about ethical concerns with disputes about the onset of human personhood. To overcome 
these issues, the reprogramming of somatic cells to produce induced pluripotent stem 
cells has become, in the last years, the “gold standard” of stem cell research. 
In 2006, for the first time, iPSCs from mouse fibroblast cells were generated in vitro by 
the groundbreaking work reported by Yamanaka (Takahashi & Yamanaka, 2006). A year 
after, the same approach was used to generate iPSC from adult human cells (Takahashi 
et al., 2007). The researchers who developed this technique called reprogramming have 
used different combinations of 24 candidate genes to induce pluripotency in differentiated 
cells (Takahashi & Yamanaka, 2006) and after several attempts, they discovered that the 
combination of only four transcription factors (Oct4, Sox2, Klf4, c-Myc) were needed. 
 
1.4.1. Reprogramming of iPSCs 
Nowadays, it is possible to revert differentiated cells into an undifferentiated state by a 
technology called cell reprogramming (Yamanaka & Blau, 2010).   
There is a vast amount of reprogramming strategies that have been developed in the last 
years. They can be distinguished as the integrative (retroviral and lentiviral vectors) and 
non-integrative methods (adenoviruses, Sendai virus vector, self-replicating episomal 
vectors), which depends on the integration of genetic material of the vector into the host 
genome. Integrative methods are more efficient, however, non-integrative methods are 
more advantageous because transgene integration bring safety concerns for therapeutic 
approaches. (Abou-Saleh et al., 2018).  
At the beginning of the iPSC technology, in the delivery of the pluripotency genes to the 
differentiated cells, retroviral vectors have been used (Stadtfeld & Hochedlinger, 2010). 
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Retroviral vectors are using RNA as genetic material and integrate to the host genome. 
Target cells that are transduced with retroviral vectors mostly depend on the exogenous 
expression of pluripotency genes and the persistence of the transgene expression in the 
host cells may cause tumour formation (Shao & Wu, 2010). Lentiviral vectors are another 
type of RNA based vectors, which are also integrative. They are more efficient than the 
retroviral vectors in the reprogramming of the differentiated cells and have a wider scale 
of the cell types that they can infect. 
To overcome the drawbacks of the integrative methods, new delivery systems have been 
developed. They include the use of adenoviruses, Sendai virus vectors, and the self-
replicating episomal vectors.  
Adenoviruses are DNA viruses whose genetic material retains in the host cell as 
extrachromosomal element. Episomal vectors are advantageous due to their long 
expression time, however they have a low efficiency of reprogramming. Another type of 
non-integrative vector, Sendai virus (SeV), which is a negative-sense single stranded 
RNA virus, was shown to have a good efficiency in the generation of iPSC and allows 
exogenous expression of the pluripotency genes (Fusaki et al., 2009).  Although the 
genetic material of SeV does not integrate into the host genome, the transgenes are 
retained in the cytoplasm of the iPSCs and should be cleared after several passages. SeV 
vector penetrates to the host cell via the sialic acid receptors that are present on the cell 
membrane of a variety of animal species. As infection, replication and subsequent 





Figure 1.6. The delivery of the pluripotency genes into the target cell using non-integrative 
methods. (Abou-Saleh et al., 2018). 
 
1.4.2. iPSCs: Generation and Characterization 
IPSCs can be generated from different origins, using distinct reprogramming methods 
and initial cell sources.  
Firstly, somatic cells from a patient are collected and cultured following specific 
protocols and under appropriate conditions (Figure 1.7).  
The cell source can be from different origins such as fibroblasts, hepatocytes, B and T 
lymphocytes, keratinocytes, blood cells (cord blood cells, peripheral blood cells), and 
urine cells (Raab et al., 2014; Singh et al., 2015; Zhao et al., 2013). The choice of the cell 
type will depend on several factors such as the availability of the cells, the reprogramming 
efficiency and non-invasive collection.  
The accessibility and the reprogramming efficiency are some of the advantages of using 
fibroblasts, however, the risk of infection and chromosomal aberrations whilst taking 
biopsies are the drawbacks of using them. Peripheral blood cells are another type of cell 
sources, which is also easily accessible. When compared to fibroblasts, they require less 
effort in maintenance in the cell culture before the reprogramming experiments. Urine 
cells are readily available and accessible to be collected without the need of medical 




After the establishment of the patient-derived somatic cell culture, they are transduced 
with the amenable vector that carries the pluripotency factors (Oct4, Sox2, Klf4, c-Myc). 
The newly reprogrammed colonies will be selected and further expanded to generate 
single origin iPSCs.  
 
 
Figure 1.7. Processing of iPSC: from the patient to the therapeutics. (Yamanaka & Blau, 
2010). 
 
Once clonally selected and expanded, these cells can be used to accurately reflect the 
patients’ disease phenotypes, not only for understanding the genetic mechanisms leading 
to the disease itself, but also for drug screening efforts aimed to the identification of 
potential personalized treatment therapies. This requires either the optimization of the 
current iPSC culturing protocols such as the maintenance of iPSC, the passaging type of 
the operator, and the preparation of the feeder cell layer are some of the variables that 
hinders reproducibility and need to be improved (Nagasaka et al., 2017). 
 
Once the iPSCs are successfully generated, they need to be characterized according to a 
set of well-established criteria. 
Morphologically, iPSCs display a high nucleus to cytoplasm ratio and form compact 
colonies with defined borders (Wakao et al., 2012). Additionally, as being pluripotent 
cells, they should express key pluripotency genes such as Oct3/4, Sox2, Klf-4, and c-Myc 
and be capable of self-renewal and differentiating into cells provenient of the three germ 
layers (Yu et al., 2007). The proliferation rate of iPSCs are also similar to ESCs, ranging 





1.4.3. Patient-derived hiPSC-CMs 
 
A number of disease modelling systems involving iPSCs are being pursued to model 
cardiac diseases, mainly cardiomyopathies (Kavyasudha et al., 2018). Two examples of 
disease modelling of cardiomyopathies (in familial cardiomyopathy and Barth Syndrome) 
using hiPSC-CMs demonstrated the disease phenotype in the patient derived hiPSC-CMs 
in vitro (Wang et al., 2014; Sun et al., 2012). 
Another potential of patient-derived hiPSCs is in the replacement of the damaged cardiac 
tissue. This therapeutic approach aims to replace the lost cardiomyocytes in the heart 
tissue with the patient’s own cells, which can be generated using chemically-defined 
medium in vitro. However, the in vitro differentiation of the CMs do not ensure the 
generation of mature CMs, which is desired for a potential transplantation (Dunn & 




















The development of the heart requires the interplay of many components in a living 
organism during the developmental stage. CHDs and/or laterality defects arise from the 
disruption of the normal cardiac development, whose aetiology is not fully understood. 
Considering the great numbers of affected patients from CHDs, there is a high burden on 
the shoulders of the patients themselves, and the health system all over the world. 
The advances in the surgical procedures and technologies have made notable 
improvements for the CHD patients. In addition to that, the research in cardiac 
development has enabled us to obtain a wider knowledge in the field. However, the 
traditional research poses limitations and we need a more elaborate knowledge in the 
steps of cardiac development in order to explain the normal and disrupted development 
of the heart and subsequently discover therapeutic agents. Although some of the key 
genes that are responsible in cardiac development are well conserved in the model 
organisms that are commonly used, the use of human cells will provide a more direct and 
precise knowledge than the other model organisms. 
Therefore, the objective of this study has been to establish a control iPSC line for the 
DAND5 c.455G>A variant in order to shed light on the role of this gene in cardiomyocyte 
proliferation.  
The research that originates the objective of this Master’s thesis included the genetic 
screening of 38 patients diagnosed with CHDs. Two patients of this study population 
have been found to have a heterozygous non-synonymous variant in DAND5, which 
corresponds to the c.455G>A (Cristo et al., 2017).  This nucleic acid change which is 
located at the coding-region of DAND5 (exon 2) results in an amino acid change at the 
p.R152H, which substitutes histidine for an arginine in the patients. The protein product 
of this variant has shown to have a significantly decreased Nodal-inhibitory activity in a 
Nodal-dependent luciferase assay (Cristo et al., 2017). Any perturbation of DAND5 
expression in the LPM might disrupt the Nodal signalling and because the location of the 
amino acid substitution is within the functional domain of the DAND5 protein, it is 
assumed that this variant might cause an abnormal Nodal activity in the node, which may 
have contributed to disrupted left-right axis patterning. 
From the patients carrying the DAND5 variant, iPSCs have been generated and one of 
them was characterized (Cristo et al., 2017). As a straightforward and non-invasive 
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procedure, urine samples were collected from the patients and exfoliated renal epithelial 
cells were chosen as the cell source of the reprogramming. Also, the urinary cells possess 
a comperatively high reprogramming efficieny. The reprogramming was performed using 
Sendai virus (SeV), which is a non-integrating vector and introduces the key pluripotency 
genes (Oct3/4, Sox2, Klf4, c-Myc) to the target cells.  
In this Master’s study, based on the previous research of our lab, a DAND5-control 
human iPSC line was established and characterized using appropriate tools that 
determines the transgene-free status, pluripotency, in vitro differential potential, 

































2. MATERIALS AND METHODS 
2.1. Ethical Approval 
All the experimental protocols were approved by the Ethics Committee of the NOVA 
Medical School (Protocol N.°13/2016/CEFCM) and by the National Committee for Data 
Protection (CNPD, Permit N.° 8694/2016), according to European Union legislation. 
Written informed consent was obtained from patient guardian prior to sample collection. 
The biological samples collected were anonymized to ensure the confidentiality and 
privacy of patients and data. 
2.2. iPSC Source and Maintenance 
Exfoliated renal epithelial (ERE) cells from a healthy Caucasian adult donor, without any 
alteration in the DAND5 gene to serve as control cell line were previously collected and 
reprogrammed into iPSCs using the CytoTune™-iPS 2.0 Sendai Reprogramming Kit 
(Thermo Fisher Scientific) (Cristo, 2016). 
After iPSCs generation, the cells were cryopreserved in Cryopreservation Medium 
(Thermo Fisher Scientific) or Essential 8ä Medium (Thermo Fisher Scientific) with 10% 
dimethyl sulfoxide (DMSO) at -150°C until further utilization.  
2.3. Cell Culture Conditions of Human iPSCs 
The culturing of the human iPSCs were carried out in Biosafety Level 2 (BL-2) 
laboratory, in an incubator exclusively used for stem cells, at 37°C, in atmospheric O2 
and 5% CO2.  
Essential 8ä Medium (Thermo Fisher Scientific) was used for the maintenance of the 
human iPSC in culture with the addition of ROCK-inhibitor (RevitaCellä Supplement 
100X, Thermo Fisher Scientific) in 1:100 dilution on the day of passage. Medium was 
changed every day. Cells were passaged every three or four days, when they reached 85% 
confluency, using TrypLEä Select Enzyme 1X (Thermo Fisher Scientific). 6-well plates 
(Thermo Fisher Scientific) were used for the incubation of the cells along with Geltrex™ 
LDEV-Free hESC-qualified Reduced Growth Factor Basement Membrane Matrix 




2.4. Characterization of Human DAND5-control iPSC Line 
The workflow of the characterization of the generated iPSC line started with the 
sequencing analysis to confirm the lack of any nucleotide substitution in exon 2 of 
DAND5 gene. After that, short tandem repeat (STR) analysis of the ERE cells (cell 
source) and the generated iPSCs confirmed that the somatic cells used for reprogramming 
and derivative stem cell line are genetically identical iPSCs after the reprogramming 
process.  
Then, we tested the transgene-free status of the iPSCs by real-time quantitative 
polymerase chain reaction (RT-qPCR). Next, Mycoplasma test has been performed to 
prove the lack of Mycoplasma contamination of the culture medium and cells. 
Subsequently, in order to assess the pluripotency of the iPSCs, RT-qPCR and 
immunocytochemistry (ICC) assays were performed. In addition to these assays, 
embryoid body formation assay was used to test the in vitro differentiation potential of 
the iPSCs. Lastly, the chromosome stability of the iPSC cells, over 20 passages, was 
verified by the analysis of the karyotype. 
 
2.4.1. Embryonic Stem Cell (ESC)-like Morphology 
The generated iPSC line displayed ESC-like morphology; mainly being characterized by 
the high nucleus to cytoplasmic ratio, formation of the colonies with defined borders. The 
cells in culture have routinely been inspected under the microscope whilst changing the 
culture medium, and prior to cell passages. 
 
2.4.2. DNA Sequencing 
To confirm the absence of the c.455G nucleotide in the established DAND5-control cell 
line, genomic DNA was extracted using ISOLATE II Genomic DNA kit (Bioline). Then, 
using the primers indicated in Annex III, Table 1.4, exon 2 of DAND5 was amplified by 
PCR and purified using NZYGelpure kit (NZYTech) according to the PCR protocol in 
Annex I-1. Direct bidirectional DNA sequencing was conducted by STAB VIDA 
(http://www.stabvida.com/). The sequencing data was analysed using 4Peaks software v 
1.8 and compared with consensus sequences obtained from the human genome databases 




2.4.3. Short Tandem Repeats (STR) Analysis 
Genomic DNA from DAND5-control iPSCs and corresponding ERE cells were extracted 
using ISOLATE II Genomic DNA kit (Bioline) according to the manufacturer’s 
instructions. The DNA elutions were conducted from ~1x106 cells. After the quality 
control procedure of the sample in agarose gel electrophoresis, DNA was amplified with 
multiplex PCR using PowerPlex 16 Kit. Analyzed loci are as follows: D351358, TH01, 
D21511, D18551, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta D, 
Amelogenin, vWA, D8S1179, TPOX, FGA. 
The sequencing of the DNA was performed using ABI 3100 DNA Analyser and the 
genotype analysis was done by GeneMarker HD software v 1.75. The steps after the 
extraction of the genomic DNA were executed by STABVIDA. 
 
2.4.4. Transgene-free Status 
Quantitative real time PCR was performed to assess the absence of Sendai virus (SeV) 
transgenes with primers suggested in the CytoTune-iPS 2.0 Sendai Reprogramming Kit 
(see Table 1.3. in Annex III). To do that, we used cDNA of the DAND5-control iPSCs at 
passage 29, diluted 1:5 and, cDNA from an early passage (4) of those cells as a positive 
control and cDNA from exfoliated epithelial renal cells as a negative control. 
 
2.4.5. Mycoplasma Contamination Detection 
Mycoplasma contamination was assessed by collecting Essential 8ä Medium from the 
iPSCs that were grown in cell culture. Afterwards, PCR was carried out with the primers 
named Mycoplasma and listed in Table 1.5, in Annex III. As a positive control, a sample 
contaminated with Mycoplasma was used, whereas the stock medium was used as a 
negative control. 
 
2.4.6. RNA Extraction, cDNA Synthesis and qRT-PCR 
Total RNA of approximately 1x106 cells was extracted and purified from control iPSC 
line, H9 human embryonic stem cell line as a positive control and exfoliated renal 
epithelial cells using TRIzol Reagent (Invitrogen) plus Direct-zol™ RNA MiniPrep kit 
(Zymo Research) according to the manufacturer's instructions. 
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After the total RNA was obtained from the iPSCs, cDNA synthesis was performed using 
1000 ng RNA and with the RevertAid RT Reverse Transcription Kit (Thermo Scientific). 
PCR of cDNA synthesis were carried out at temperatures 65°C for 5’, 42°C for 60’, 72°C 
for 5’, in C1000ä Thermal Cycler (BioRad) instrument. cDNA was then diluted 1:10, 
with nuclease-free water, and 2 µl were used to quantify by qRT-PCR the expression of 
the target genes. qRT-PCR was performed on an Applied Biosystems® 7500 Real-Time 
PCR machine and reactions were run with SYBR® Select Master Mix (Applied 
Biosystems). CT-values were normalized to the geometric mean of the two housekeeping 
genes GAPDH and β-actin and with H9 human embryonic stem cell (ESC) line as 
reference (set to 1). 
 
2.4.7. Detection of Pluripotency Markers - Immunocytochemistry 
ICC of the iPSCs was performed on Geltrex-coated cover slips in 24-well-plates, when 
the cells reached 50-60% confluency. 
One day after, cells were initially washed with PBS and fixed with 4% formaldehyde for 
30’, then washed with PBS, permeabilized with PBS with 0,1% Triton-X-100 for 30’ (this 
step was shortened to 7’ for the cell surface protein SSEA4), blocked with blocking 
solution (BS: 0,4g BSA, 0,04 g NaN3, 1,5g glycine in 200ml PBS) for 30’ and incubated 
with primary antibodies (see Annex III) overnight at 4°C. In the next day, the cells were 
washed with BS, and incubated with secondary antibodies (see Annex III) overnight at 
4°C. At day 3, cells were washed again with BS, incubated with 4',6-diamidino-2-
phenylindole (DAPI) 1:1000 in PBS for 35’ in dark, washed and kept in PBS.  
Coverslips were then carefully picked and mounted on a microscope slide covered with 
Mowiol mounting media, and sealed with nail polish to fix the coverslips on the slides. 
The images were immediately acquired in confocal microscope (LSM710, Zeiss) or 
widefield fluorescent microscope (Z2 Axio Imager, Zeiss).  
 
Note: All the washing steps were repeated three times, 5 minutes each. 
 
2.4.8. Detection of in vitro Differentiation Potential 
The spontaneous differentiation potential of the iPSCs were analysed using the hanging 
drop method to generate embryoid bodies (EBs). After regular passaging, at D0, 2000 
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cells per 20µl were resuspended with EB formation media (4mg/ml PVA, RevitaCellä 
Supplement 1X in Essential 8ä Medium, filtered). on 100 mm culture dish. In order to 
grow the EBs, a growth medium (DMEM with 20% FBS, 1% Glutamine, 1% NEAA, ß-
mercaptoethanol and 1% Pen Strep) was previously prepared. At D2, the EB drops were 
suspended in Essential 8ä and EB growth medium (1:1). From D4, only EB growth 
medium was used to grow the cells. When the EBs were big enough, normally at D5, the 
EBs were manually picked and placed on cover slips coated with Geltrex on a 24-well-
plate. Medium was changed every other day until the distinct cell types were observed 
under the microscope. Therefore, normally between days 19-21, the cells were fixed and 
the immunocytochemistry assay started as described above. 
 
2.4.9. Karyotype Analysis 
Karyotyping was performed according to the protocols from Laboratório de Citogenética 
e Genómica, Faculdade de Medicina da Universidade de Coimbra. Briefly, chromosome 
analysis was performed using GTG high resolution banding technique, according to 
standard procedures with a minimum of 10 metaphase spreads analyzed. Analysis of 
GTG-banded chromosomes was performed at a resolution of 400 bands per haploid 
genome and karyotypes were established according to the International System for 












3.1. Morphology of DAND5-control iPSCs 
After generation and clonal expansion of the DAND5-control iPSC line, the cells 
continued to display a typical small, round shape, and tightly packed ESC-like 
morphology with defined borders, a high nucleus/cytoplasm ratio with prominent nucleoli 
as presented in Figure 3.1., suggesting that the generated iPSC lines were successfully 
reprogrammed. 
 
Figure 3.1. Generated DAND5-control iPSCs in culture. A. 5X, B. 10X, C. 20X. Characteristic 
iPSC properties are observable such as defined borders of the colonies, large nucleoli of the cells, 
and their round shape. The cells are at passage 27, and the image is acquired with a Zeiss Axiovert 
40 CFL. 
 
3.2. Sequencing Analysis of DAND5 Exon2 
 
The main purpose of this thesis was the establishment of a DAND5-control iPSC line. 
with a wild-type allele, G, in the position c.455 of the exon 2 of the DAND5 gene to serve 
as control for the DAND5 c.455 G>A line generated before. Therefore, DNA Sanger 
sequencing confirmed the homozygous presence of the c.455G>G allele in the exon 2 of 
DAND5 gene, corresponding to a R152R amino acid protein, in one clone of the iPSC 





Figure 3.2. Forward and Reverse sequencing of DAND5 exon2. DNA sequence confirming 
the normal homozygous c.455G genotype in the DAND5-control cell line. The arrow at the left 
image indicates the unaltered genotype 455G in the forward sequence, whereas the arrow at the 
right image shows the corresponding cytosine in the reverse sequence. 
 
3.3. STR Analysis 
 
Short tandem repeat (STR) analysis is a tool used to identify unknown samples based on 
the repeat number of nucleic acids in a number of different independent loci. The use of 
different loci increases the accuracy of the technique, since the probability of someone 
sharing the same repeat number will be less likely (McNamara-Schroeder et al., 2006).  
For the characterization of this DAND5-control iPSCs line, 16 loci in donor cells (ERE 
cells) and the iPSCs have been compared to ensure the identity of the iPSCs after the 
reprogramming. The result, presented in the Fig. 3.3 showed that all the 16 loci from both 






Figure 3.3. STR analysis of the iPSC in comparison with the ERE cells. Sample UC13 
represents the donor ERE cells, whereas Sample iUC13 7.37 represents the reprogrammed iPSCs. 
Listed numbers indicate the repeat number of each specified loci for both alleles, in each sample, 
whereas X and Y stands for the sex chromosomes. 
 
3.4. Clearance of the Transgenes – Lack of Transgene Expression 
(qPCR) 
 
The use of virus particles to reprogram the somatic cells present some safety issues 
concerning the integration of the virus genome in the host cells or the persistence of the 
virus in the cytoplasm of the cells. Thus, the proof of the transgene-free cell line is a 
standard procedure in our day to validate the cell line. The Sendai virus vector used in the 
reprogramming of the ERE cells into iPSCs in this work is a modified form of the wild 
type SeV, which is a transmissible and pathogenic RNA virus (Fujie. et al., 2014). This 
modified version of the SeV lacks the fusion protein, which hinders the generation of the 
infectious particles in the transduced cells. Moreover, the functional mutations in several 
proteins of the virus facilitates the removal of the virus from the infected cells. Therefore, 
this system is non-pathogenic to humans and non-transmissible, does not integrate into 
the genome of the transduced cells and the transgenes of the SeV are expected to be 
diluted in the generated iPSCs after several passages in culture.  
Even though the modified Sendai virus is non-pathogenic and non-transmissible, the 
expression of the pluripotency genes should only represent the endogenous expression of 
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those genes. Therefore, we evaluated the lack of the transgenes in the generated iPSC line 
by quantitative real-time PCR.  
Since the SeV is a RNA-virus, after the extraction of the RNA from the iPSC, we 
synthetized cDNA to perform a qRT-PCR using primers that amplify Sendai virus-
specific genes. Four different sets of primers have been used in the qRT-PCR experiment; 
SeV, KOS, Klf-4, and c-Myc. KOS consists of the human Klf-4, human Oct3/4, and 
human Sox2. According to the Fig. 3.4, the iPSCs, indicated as iUC-DAND5-control, 
presented a relative expression closer to zero relative to the ERE cells (used as negative 
control), for each gene tested. This result suggests that neither the SeV vector, nor the 
SeV-Klf4, SeV-c-Myc, SeV-KOS are present in the generated DAND5-control iPSCs.  
 
 
Figure 3.4. Transgene-free status of the established iPSC cell line. Absolute quantitative real-
time PCR showing absence of the vectors and the exogenous reprogramming factor in iPSCs 
(right) and presence of the reprogramming factors in the EREr control cells (left). 
 
3.5. Mycoplasma-free Culture 
 
Mycoplasma species are known to be widely contaminating agents in cell cultures. They 
are hard to detect by visual identification due to their size and their contamination is 
problematic.  
In order to detect the Mycoplasma-free status of the iPSCs culture, we performed a PCR 
experiment using two specific sets of primers that detect the Mycoplasma genes. The 
result showed no amplification in two independent Essential 8ä media samples 
(enumerated as 2 and 3 in Fig. 3.5 for each primer set) taken from different plates used 
for the culturing of the iPSC cells (Fig. 3.5). As a positive control for both primer sets, 
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cells known to be contaminated with Mycoplasma have been used. As negative control, 
we used the Essential 8ä media taken from the stock solution and incubated at 37°C with 
no cells. 
 
Figure 3.5. Mycoplasma contamination test. PCR showing the absence of Mycoplasma in the 
culture conditions of the iPSCs (1kb+ DNA Ladder was used as reference). 
 
3.6. Expression of Pluripotency Factors – Gene Level 
 
The pluripotency factors are expressed solely by the pluripotent cells and are specific 
markers for those cells. Equally, the reprogramming of the cells does not occur naturally, 
therefore terminally differentiated cells are expected to have no significant expression of 
pluripotency genes in combination. 
Therefore, the demonstration of expression of pluripotency factors in the induced PSCs 
are very crucial for their characterization.  
To confirm the expression of pluripotency markers at mRNA level, gene expression 
analysis through quantitative RT-PCR was performed in the DAND5-control iPSC line. 
According to our analysis (Fig. 3.6), the expression of the endogenous pluripotency genes 
OCT3/4, NANOG, SOX2, KLF4 and NODAL in the established DAND5-control iPSC cell 
line is equal (OCT4) or higher (NANOG, KLF4, SOX2, NODAL) than the expression of 
those genes when in common human embryonic stem cells line (H9). Furthermore, these 
pluripotency genes were absent in exfoliated renal epithelial cells, except for KLF4 that 





Figure 3.6. Relative expression of pluripotency genes NANOG, OCT4 KLF4, SOX2, and 
NODAL. mRNA expression levels of endogenous pluripotency markers in H9 cells (black - 
positive control), ERE cells (blue) and iUC-DAND5_455/control line (red). 
 
3.7. Expression of Pluripotency Factors – Protein Level 
 
In addition to the expression of pluripotency factors at mRNA level we also assessed the 
pluripotency state of the DAND5-control iPSC line at protein level. As we can see in the 
Fig. 3.7, immunofluorescence analysis confirmed the presence of NANOG, OCT4, and 
SSEA4, characteristic of pluripotent embryonic stem cells, in all cells from the colonies.  
OCT4 and NANOG are the self-renewal transcription markers, and hence are stained 
within the nuclei, whereas SSEA4 is a protein expressed at the plasma membrane, in 
concordance with its intercellular staining. 
The expression of these proteins also illustrates the homogeneity and purity of the 
generated iPSC line. 





Fig. 3.7. Pluripotency of the DAND5-control cell line displayed at protein level. 
Immunofluorescence assay showing iPS cells positively stained with the pluripotency-associated 
markers OCT-4, NANOG, and SSEA4,  proving the pluripotent state of the cell line. Images were 
acquired using Zeiss LSM710 confocal microscopy. 
 
3.8. Differentiation Potential of iPSCs in vitro 
 
Pluripotent stem cells are characterized by their potential to differentiate into the three 
germ layers that give rise to all the cells of the body; endoderm, ectoderm, and mesoderm. 
As pluripotent cells, iPSCs should be able to differentiate into all these three lineages. 
To test the differentiation potential of our iPSCs, we used the hanging drop method to 
generate embryoid bodies, which allows the generation of cell clusters that are known to 
spontaneously differentiate in culture. 
From this assay, we assessed that the EBs cultured for 19 days expressed markers of the 
three germ layers: endoderm, mesoderm, ectoderm, i.e., alpha-fetoprotein (AFP), smooth 
muscle actin (SMA), tubulin beta-3 chain (TUBB3), respectively (Fig. 3.8) 
Each of the cover-slips were stained with different primary antibodies. Not all the cells 
in one single cluster expressed three germ layer markers. However, this is expected due 
to the spontaneous differentiation of the cells in vitro, where no specific differentiation 
was directed using any agent. 
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The result of this assay proved that the generated iPSCs can differentiate into three 
different cell types from three germ layers tested, which means they can differentiate into 
any cell type of the body. 
 
Figure 3.8. Spontaneous differentiation potential of iPSC in vitro. Immunofluorescence 
analyses of in vitro differentiation of EBs using specific antibodies against the endodermal marker 
α-fetoprotein (AFP), ectodermal marker βIII-tubulin (TUBB3) and mesodermal markers α-
smooth muscle actin (SMA). Nuclei were stained with DAPI (scale bars=20µm). 
 
3.9. Karyotype Analysis 
 
The reprogramming, high proliferation rate and the relatively short doubling time of 
iPSCs increases the risk of chromosome instability. Therefore, to confirm that the iPSCs 
obtained through the transduction of the CytoTune® vectors, KOS (Klf4–Oct3/4–Sox2), 
hc-Myc, and hKlf4 into the renal epithelial cells maintain a proper genomic content, we 
performed the karyotype of the patient-derived iPSCs at passage 29. As presented in the 
Figure 3.9, the karyotype of the DAND5-control iPSCs seems to be normal, presenting 
22 pairs of autosomal chromosomes and 1 pair of sex chromosomes. Nevertheless, a more 
detailed analysis of the chromosomes banding is currently ongoing to exclude possible 





Fig. 3.9. Karyotype analysis of the iPSCs. Karyotype showing the normal 46, XX chromosomal 


























4. DISCUSSION AND CONCLUSIONS 
 
TGF-ß/Nodal signalling pathway regulates the left-right axis establishment in vertebrates. 
The protein product of Cerl2 gene (DAND5 in humans), being an antagonist in this 
pathway functions by binding to Nodal protein in the mice node.  
The lack of this gene, studied in Cerl2 knock-out (KO) mice results in laterality defects 
and a significant rate of mortality caused by cardiac defects (Marques et al., 2004).  
Additionally, Cerl2 KO mice also display a massive increase of the ventricular cardiac 
walls due to an increased mitotic index of the cardiomyocytes, and more importantly from 
prolonged TGF-ß/Nodal signalling in those heart cells (Arauȷó, Marques & Belo, 2014). 
The increased levels of nuclear ß-catenin in Cerl2 KO mice also shows that the lack of 
Cerl2 affects another pathway involved in cardiomyocyte proliferation. This finding 
shows that the lack of Cerl2 in mice does not only cause laterality defects as previously 
thought, but also specifically regulates the cardiomyocyte proliferation through Wnt/ß-
catenin and TGF-ß/Nodal signalling pathway.  
In a prevıous study ın our lab, that ıs the basis fort he work developed in thıs thesıs, two 
patients were identified with a missense variant in the exon 2 of the DAND5 genes 
(c.455G>A) (Cristo et al., 2017). Since an increase of the Nodal signalling was observed 
due to this variant, it was hypothesized, that similar to Cerl2 KO mice, the cardiomyocyte 
proliferation and maturation could also be affected in these patients. 
In order to test this hypothesis, the generation of a patient-specific DAND5 human iPSC 
line, as well as a suitable related control one was undertaken. Therefore, in the work 
presented in this Master’s thesis, a DAND5-control human iPSC line was characterized 
proving their transgene-free and pluripotent status, in vitro differential potential, and 
karyotype stability. The origin of the control cells was the ERE cells from a healthy male 
Caucasian without any alteration in DAND5. This donor is related to the patient that 
carries the DAND5 variant c.455G>A.  
An ideal control in this type of studies would be an isogenic cell line derived from the 
patient’s own cells, sınce they have the same genotype as the patıent, just mısmatchıng 
ın one nucleotıde. Nerverthelese, the generation of an isogenic cell line was not possible 
by the time of this work. Moreover, in the future, and having this cell lıne characterized 
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we can induce the c.455G>A variant and clearly confırm the phenotype of those cells and 
exclude or not the action of other modifiers variants that the patient can have. 
 
Although adult cardiac stem cells might be an alternative source to study the cardiac 
diseases, the amount of the cells obtained from patıents are very limited. Additionally, 
their isolation and expansion in the culture is not as easy as in iPSCs. Also, immature 
electrical phenotypes of the derived cells makes this application less effective. 
In the future, the DAND5 variant and the control cell line could be differentiated into 
cardiomyocytes, and subsequently, the proliferation rates of the ventricular 
cardiomyocytes could be investigated and compared in vitro. The establishment of this 
disease modelling at a later stage can be exploited for the discovery of the relevant drug 
candidates and serve for translational medicine purposes. 
In spite of its promising potential, iPSC technology still is a recent methodology and its 
limitations need to be overcome. The improvement of new reprogramming methods that 
have higher reprogramming efficiency might accelerate the generation of iPSC from adult 
cells. Once reprogrammed, these cell should be expanded and mass produced for 
translational purposes. 
Another hurdle that needs to be surpassed is to provide safety in case of the transplatation 
of cardiomyocytes. Reprogramming by the direct delivery of proteins or the avoidance of 
the use of viral methods would assure the safety requirements. 
The differentiation of the iPSCs into the different subtypes of cardiomyocytes represents 
another limitation and the development of protocols to generate only specific subtypes of 
cardyomiıocytes need to be ensured to avoid the cardiac arrthymias caused by distinct 
beating patterns. 
Other technologies such as heart-on-a-chip devices, that are mainly used in mimicing the 
cardiac tissue are also very promising approaches. The generation of iPSC and their 
subsequent differentiation into cardiomyocytes can provide a source as ‘bioink’ to 3D 
print a cardiac tissue.  
Although the clinically approved therapies need to satisfy the requirements of the 
authorities, in the future, iPSC based therapies can be used as a personalized medicine 
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98°C   1:00 min. x1 
98°C 00:15 min.  
65°C 00:25 min.  
72°C 00:20 min. x35 
72°C 00:30 min.  
 
2. cDNA Synthesis Protocol 
 
1. Defrost the components of the RevertAid First Strand cDNA Synthesis Kit oligodT, 
RT Buffer, RiboLock, dNTPS (10mM) and the RNA samples. 
2. Prepare the PCR tubes, and add the relevant amounts of RNA, oligodT, and nuclease 
free (NF) water. 
The total amount of the mix should be 12,5 µl (1µl oligodT + 1000ng RNA + NF water). 
3. Incubate the PCR tubes at 65°C for 5 minutes. After 5 minutes, place the samples 
immediately on ice (or set 12°C after the first step in thermal cycler instrument). 
4. Calculate the master mix amount you need and prepare it in a 1,5ml microcentrifuge 
tube according to the table below: 
RT Buffer 4 µl 
RiboLock 0,5 µl 
dNTP 2 µl 
RT enzyme 1 µl 
Total (per sample): 7,5 µl 
 
5. Pipette 7,5µl of the master mix to each sample (the final amount will thus be 20 µl per 
sample) and start the PCR reaction at 42°C according to the temperatures below: 
65°C 5:00 min. 1x 
12°C ¥      1x 
42°C 60:00 min.  
72°C 5:00 min. 












1. Defrost SYBR Green (once thawed, protect from the light), primer pairs, and the 
cDNAs, place on ice. 
2. Calculate the qPCR mix amount you need per primer pair and prepare it in a 1,5ml 
microcentrifuge tube according to the table (amounts per sample) below: 
SYBR Green 7,5 µl 
Forward Primer 1,0 µl 
Reverse Primer 1,0 µl 
H2O 3,5 µl 
Total: 13 µl 
 
The list of controls:  
Positive control: H9 commercial stem cell line 
Negative control: Exfoliated renal epithelial (ERE) cells 
qPCR control: qPCR mix without the cDNA (NF H2O instead) 
 
3. Label the corners of the qPCR plate according to the gene name tested.  
4. Pipette 13µl of qPCR mix with the relevant primers in each well (you may want to use 
triplicates). Pipette them at the bottom of the wells. 
5. Pipette 2µl of cDNA at the corners of the well.  
6. Centrifuge the qPCR plate for 1 min. at 1,200 rpm. 
7. Place the qPCR plate in the instrument, set up the conditions and start the experiment 
according to the list below: 
 
PCR conditions of the pluripotency and the house-keeping genes: 
NANOG, OCT3/4, ß-ACTIN:  
 
95°C 10:00 min. x1 
95°C 00:30 min. 
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55°C 00:15 min.  
72°C 00:30 min. x40 
 
hSOX2, hNODAL, KLF-4:  
 
95°C 10:00 min. x1 
95°C 00:30 min.  
65°C 00:15 min.  




95°C 10:00 min. x1 
95°C 00:30 min.  
61,3°C 00:15 min.  
72°C 00:30 min. x40 
 
ANNEX III 
Table 1.1. Antibodies used in immunocytochemistry assay 
 
Antibody Marker Type Dilution Information 
Rabbit anti-
NANOG 





























































Table 1.2. Primer sequences of Pluripotency Genes and House-keeping Genes 
 


























Table 1.3. Primer sequences of Sendai-virus specific genes 
 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
SeV GGATCACTAGGTGATATCGAGC  ACCAGACAAGAGTTTAAGAGATATG
TATC 
 
Sev-KLF4 TTCCTGCATGCCAGAGGAGCCC  AATGTATCGAAGGTGCTCAA 
Sev-C-MYC TAACTGACTAGCAGGCTTGTCG  TCCACATACAGTCCTGGATGATGAT
G 
Sev-KOS ATGCACCGCTACGACGTGAGCGC  ACCTTGACAATC CTGATGTGG  
 
Table 1.4. Primer sequences of DAND5 exon 2 
 





Table 1.5. Primer sequences of Mycoplasma 
 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Pair 1 CTGCAGATTGCAAAGCAAGA CCTCCTTCTTCACCTGCTTG  
Pair 2 GGCGAATGGGTGAGTAACACG  CGGATAACGCTTGCGACCTATG 
 
 
 
